Healthcare Industry News: nitinol stent
News Release - May 16, 2006
Physicians Now Have a New Treatment Option for Patients With a Common Vascular Disease Affecting the LegsS.M.A.R.T.(R) Stent for Primary Stenting of Iliac Artery Now Available
WARREN, N.J., May 16 (HSMN NewsFeed) -- Patients with vascular disease affecting the legs now have a new treatment option. Cordis Endovascular, a division of Cordis Corporation, today announced the availability of the S.M.A.R.T.® Stent for primary stenting in the iliac artery, which allows blood flow to the legs. It is the first nitinol stent approved for primary stenting of the iliac artery.
"The S.M.A.R.T.® Stent showed excellent patency and procedural success results, and in some situations may be placed with higher precision compared to the Wallstent(*)," said Donald, J. Ponec, MD, Tri City Medical Center, Oceanside, CA and Principal Investigator of the Cordis Randomized Iliac Stent Project (CRISP) trial. CRISP, published in the Journal of Vascular and Interventional Radiology (Vol. 15 No.9 September 2004), was designed to evaluate the equivalence of the S.M.A.R.T.® nitinol stents to the stainless steel Wallstent iliac endoprosthesis in the treatment of iliac artery disease after suboptimal percutaneous transluminal angioplasty (PTA).
The safety and effectiveness of the S.M.A.R.T.® Stent was established based on data from the prospective, randomized, multi-center CRISP clinical trial.
John Laird, MD, WA Hospital Center, Washington, DC and a CRISP trial investigator said, "The S.M.A.R.T.® Stent is the only nitinol stent with the iliac indication. Clinical evidence from CRISP suggests that physicians can use this system with confidence."
"Cordis Endovascular is pleased to make the S.M.A.R.T.® Stent, now with an iliac indication, available to physicians, hospitals and patients," said Dennis Donohoe, M.D., Vice President, Worldwide Clinical and Regulatory Affairs, Cordis Corporation. "Robust clinical evidence from the randomized, multi-center CRISP trial demonstrates that our stent may contribute to greater procedural success and more accurate stent deployment.
Peripheral Arterial Disease (PAD)
PAD is common, affecting millions of individuals, as it affects blood flow to vital arteries outside the heart. All individuals with PAD face a very high short term risk of heart attack and stroke, and PAD can be associated with major symptoms that can impair quality of life, lead to loss of independence, limb loss, or death.
In PAD, fatty deposits build up in the inner lining of artery walls in the non-coronary arteries to any other vital organ. Any artery narrowing in any part of the body is associated with a nearly equal risk of heart attack, stroke, or death. Yet, peripheral arterial disease also places other vital organs at risk.
About Cordis Endovascular
Cordis Endovascular is a recognized leader in endovascular research and development. It has the resources to make breakthrough treatments possible along with the reputation for delivering trusted, quality products and value that is expected by our customers.
Cordis Endovascular is a worldwide supplier of interventional and diagnostic medical products including nitinol and stainless steel stents, CTO technologies, vena cava filters, balloon catheters and accessories. It is committed to serving the cardiology, radiology and vascular surgery communities through the development of groundbreaking technologies for the treatment of peripheral vascular disease.
Cordis Endovascular constantly seeks solutions to the human anatomy's most challenging problems, such as carotid artery disease, aortic aneurysm, superficial femoral artery disease and venous thrombotic disease.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through research, development and innovation, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease. For more information about Cordis, please visit www.cordis.com.
(*)Wallstent is a trademark of Boston Scientific Corporation or its affiliates.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.